×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
🎬
Demo Video
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Demo Video
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Event: MDS 2026 — Emerging Therapeutics in Parkinson's Disease
event
1,024 words
Contents
MDS 2026 — Emerging Therapeutics in Parkinson's Disease
No AI portrait yet
Generate portrait ✦
Agent Input
💡 Improve this page
🌐 Cross-references
Wikipedia
Related Hypotheses (101)
TREM2-Dependent Microglial Senescence Transition
Score: 0.62
TREM2-mediated microglial tau clearance enhancement
Score: 0.62
Low Complexity Domain Cross-Linking Inhibition
Score: 0.62
Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro
Score: 0.61
Restoring Neuroprotective Tryptophan Metabolism via Targeted
Score: 0.61
Correcting Gut Microbial Dopamine Imbalance to Support Syste
Score: 0.61
Glycosaminoglycan Template Disruption Approach
Score: 0.60
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.58
Extracellular Vesicle Biogenesis Modulation
Score: 0.58
CX43 hemichannel engineering enables size-selective mitochon
Score: 0.57
Fractalkine Axis Amplification via CX3CR1 Positive Allosteri
Score: 0.56
Liquid-Liquid Phase Separation Modifier Therapy
Score: 0.55
Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy
Score: 0.55
Glymphatic System-Enhanced Antibody Clearance Reversal
Score: 0.54
Blood-Brain Barrier SPM Shuttle System
Score: 0.53
Cryptic Exon Silencing Restoration
Score: 0.53
Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioener
Score: 0.53
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.51
Microglia-Derived Extracellular Vesicle Engineering for Targ
Score: 0.48
RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Score: 0.47
← Prev
pg 5/6
Next →
Related Analyses (30)
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · archived
Show 25 more
Related Experiments (30)
Non-Motor Symptom Progression in Parkinson's Disease — Mecha
clinical · proposed · Score: 0.40
Sirtuin Pathway Dysfunction Validation in Parkinson's Diseas
clinical · proposed · Score: 0.40
Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechani
clinical · proposed · Score: 0.40
Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper
clinical · proposed · Score: 0.40
Peroxisome Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne
validation · completed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Parkinson's Disease Subtype Classification — Precision Medic
clinical · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
GLP-1 Agonist Responder Prediction Study — Precision Medicin
clinical · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Levodopa Response Determinants in PSP — Biomarker-Guided Pre
clinical · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · completed · Score: 0.40
Metabolic Syndrome-Parkinson's Disease Axis Clinical Trial
clinical · proposed · Score: 0.40
Down Syndrome Alzheimer's Disease: Mechanisms and Therapeuti
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Prodromal Parkinson's Disease Biomarker Development — Early
clinical · proposed · Score: 0.40
GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40
Tau Pathology Initiation Zone Identification
clinical · proposed · Score: 0.40
Show 25 more
See Also (15)
Neuroinflammation PET Imaging in CBS/PSP
diagnostic · KG edge: inhibits
BACE1 (Redirect)
redirect · KG edge: references
GFAP (Redirect)
redirect · KG edge: references
TFEB (Redirect)
redirect · KG edge: references
TLR4 (Redirect)
redirect · KG edge: references
TREM2 Protein (Triggering Receptor Expressed on Myeloid
entity · KG edge: references
BDNF Gene
gene · KG edge: references
C3 — Complement Component 3
gene · KG edge: references
NURR1 Gene
gene · KG edge: references
PPARGC1A Gene
gene · KG edge: references
SIRT6 Gene
gene · KG edge: references
APOE contributes to Alzheimer's disease by regulating b
hypothesis · KG edge: references
NLRP3 Inflammasome Hypothesis in Parkinson's Disease
hypothesis · KG edge: references
CX3CR1 Modulation Therapy for Neurodegeneration
idea · KG edge: references
VCP Proteostasis Modulation Therapy for ALS/FTD
idea · KG edge: references
Show 10 more
Knowledge Graph (2 edges)
bradykinesia
biomarker_for
MDS-UPDRS bradykinesia subscale
MDS-UPDRS Part I Cognition Score
biomarker_for
Dementia
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.